The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company’s cash and cash equivalents totaled 231 million USD.

Based on the current rate of capital expenditure, this cash reserve is expected to sustain the company’s operations until 2028. This financial indicator has significantly boosted market confidence in the company’s R&D continuity. As an innovative pharmaceutical company specializing in the development of antibody-drug conjugates (ADC), ample cash flow will ensure the advancement of its core pipeline and the expansion of clinical research. Notably, the forecast of sufficient capital until 2028 provides a clear strategic planning window for potential partners and investors. In a challenging financing environment for the biotech industry, ADC Therapeutics SA demonstrates a differentiated advantage through its robust financial position. Company management stated that existing funds will be prioritized to accelerate key clinical programs while exploring commercial partnerships to maximize asset value.